ID

DB00223|APRD00921||

名称

Diflorasone

描述

Diflorasone is a topical corticosteroid used to treat itching and inflammation of the skin.

cas号

2557-49-5

唯一标识码

T2DHJ9645W

状态

solid

组

approved,

指示

For relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

药效学

Like other topical corticosteroids, diflorasone has anti-inflammatory, antipruritic, and vasoconstrictive properties. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Diflorasone is a potent topical corticosteroid that should not be used with occlusive dressings. It is recommended that treatment should be limited to 2 consecutive weeks and therapy should be discontinued when adequate results have been achieved.

作用机制

The precise mechanism of the antiinflammatory activity of topical steroids in the treatment of steroid-responsive dermatoses, in general, is uncertain. However, corticosteroids are thought to act by the induction of phospholipase A₂ inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A₂.

毒性

Topically applied diflorasone can be absorbed in sufficient amounts to produce systemic effects. Symptoms of overdose include thinning of skin and suppression of adrenal cortex (decreased ability to respond to stress).

代谢

Metabolized, primarily in the liver, and then excreted by the kidneys.

吸收

Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption.

半衰期

分类

description:This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
direct-parent:21-hydroxysteroids
kingdom:Organic compounds
superclass:Lipids and lipid-like molecules
class:Steroids and steroid derivatives
subclass:Hydroxysteroids
alternative-parent:11-beta-hydroxysteroids
alternative-parent:17-hydroxysteroids
alternative-parent:20-oxosteroids
alternative-parent:3-oxo delta-1,4-steroids
alternative-parent:Alkyl fluorides
alternative-parent:Alpha-hydroxy ketones
alternative-parent:Cyclic alcohols and derivatives
alternative-parent:Cyclic ketones
alternative-parent:Delta-1,4-steroids
alternative-parent:Fluorohydrins
alternative-parent:Gluco/mineralocorticoids, progestogins and derivatives
alternative-parent:Halogenated steroids
alternative-parent:Hydrocarbon derivatives
alternative-parent:Organic oxides
alternative-parent:Organofluorides
alternative-parent:Primary alcohols
alternative-parent:Secondary alcohols
alternative-parent:Tertiary alcohols
substituent:11-beta-hydroxysteroid
substituent:11-hydroxysteroid
substituent:17-hydroxysteroid
substituent:20-oxosteroid
substituent:21-hydroxysteroid
substituent:3-oxo-delta-1,4-steroid
substituent:3-oxosteroid
substituent:6-halo-steroid
substituent:9-halo-steroid
substituent:Alcohol
substituent:Aliphatic homopolycyclic compound
substituent:Alkyl fluoride
substituent:Alkyl halide
substituent:Alpha-hydroxy ketone
substituent:Carbonyl group
substituent:Cyclic alcohol
substituent:Cyclic ketone
substituent:Delta-1,4-steroid
substituent:Fluorohydrin
substituent:Halo-steroid
substituent:Halohydrin
substituent:Hydrocarbon derivative
substituent:Ketone
substituent:Organic oxide
substituent:Organic oxygen compound
substituent:Organofluoride
substituent:Organohalogen compound
substituent:Organooxygen compound
substituent:Oxosteroid
substituent:Pregnane-skeleton
substituent:Primary alcohol
substituent:Progestogin-skeleton
substituent:Secondary alcohol
substituent:Tertiary alcohol

消除途径

种类

Adrenal Cortex Hormones
D000305
Anti-Inflammatory Agents
D000893
Corticosteroid Hormone Receptor Agonists

Corticosteroids
D000305
Corticosteroids, Dermatological Preparations

Corticosteroids, Potent (Group III)

Dermatologicals
D003879
Fused-Ring Compounds
D000072473
Hormones
D006728
Hormones, Hormone Substitutes, and Hormone Antagonists
D006730
Immunosuppressive Agents
D007166
Pregnadienes
D011245
Pregnadienetriols
D011246
Pregnanes
D011278
Steroids
D013256
Steroids, Fluorinated
D013259

盐类

DBSALT000887Diflorasone diacetate7W2J09SCWX33564-31-7BOBLHFUVNSFZPJ-JOYXJVLSSA-N494.532494.211609696

蛋白质结合

Bound to plasma proteins in varying degrees.

清除

同义词

language:english; code:; name;(6α,11β,16β)-6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
language:spanish; code:inn; name;Diflorasona
language:english; code:inn; name;Diflorasone
language:latin; code:inn; name;Diflorasonum

国际品牌

Florone EMaxiflor

配送量

产品

name:ApexiCon
labeller:Fougera Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0462-0394
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-09-30
ended-marketing-on:2014-05-31
dosage-form:Ointment
strength:0.5 mg/1g
route:Topical
fda-application-number:ANDA075374
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:ApexiCon E
labeller:Pharma Derm, A Division Of Fougera Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0462-0395
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-09-30
ended-marketing-on:2014-06-30
dosage-form:Cream
strength:0.5 mg/1g
route:Topical
fda-application-number:ANDA076263
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:ApexiCon E
labeller:PharmaDerm a division of Fougera Pharmaceuticals Inc.
ndc-id:
ndc-product-code:10337-395
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-12-20
ended-marketing-on:
dosage-form:Cream
strength:0.5 mg/1g
route:Topical
fda-application-number:ANDA076263
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Diflorasone Diacetate
labeller:E. Fougera & CO., A division of Fougera Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0168-0242
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1998-03-30
ended-marketing-on:
dosage-form:Cream
strength:0.5 mg/1g
route:Topical
fda-application-number:ANDA075187
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Diflorasone Diacetate
labeller:Versa Pharm Incorporated
ndc-id:
ndc-product-code:61748-350
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-03-08
ended-marketing-on:
dosage-form:Ointment
strength:0.5 mg/1g
route:Topical
fda-application-number:ANDA206572
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Diflorasone Diacetate
labeller:E. Fougera & CO., A division of Fougera Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0168-0243
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1999-04-27
ended-marketing-on:
dosage-form:Ointment
strength:0.5 mg/1g
route:Topical
fda-application-number:ANDA075374
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Diflorasone Diacetate
labeller:E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0168-0353
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-12-20
ended-marketing-on:
dosage-form:Cream
strength:0.5 mg/1g
route:Topical
fda-application-number:ANDA076263
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Diflorasone Diacetate
labeller:Teligent Pharma, Inc.
ndc-id:
ndc-product-code:52565-063
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-06-13
ended-marketing-on:
dosage-form:Ointment
strength:0.5 mg/1g
route:Topical
fda-application-number:ANDA210753
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Diflorasone Diacetate
labeller:Innovida Pharmaceutique Corporation
ndc-id:
ndc-product-code:71800-009
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-08-15
ended-marketing-on:
dosage-form:Ointment
strength:0.5 mg/1g
route:Topical
fda-application-number:ANDA075331
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Diflorasone Diacetate
labeller:Taro Pharmaceuticals U.S.A., Inc.
ndc-id:
ndc-product-code:51672-1296
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2000-04-24
ended-marketing-on:
dosage-form:Cream
strength:0.5 mg/1g
route:Topical
fda-application-number:ANDA075508
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Diflorasone Diacetate
labeller:Taro Pharmaceuticals U.S.A., Inc.
ndc-id:
ndc-product-code:51672-1295
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1999-05-14
ended-marketing-on:
dosage-form:Ointment
strength:0.5 mg/1g
route:Topical
fda-application-number:ANDA075331
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Diflorasone Diacetate
labeller:Riconpharma Llc
ndc-id:
ndc-product-code:51125-409
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-02-28
ended-marketing-on:2017-02-28
dosage-form:Ointment
strength:0.5 mg/1g
route:Topical
fda-application-number:ANDA207440
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Diflorasone Diacetate
labeller:Rising Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:64980-124
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-02-27
ended-marketing-on:
dosage-form:Ointment
strength:0.5 mg/1g
route:Topical
fda-application-number:ANDA207440
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Diflorasone Diacetate Oint
labeller:Sola Pharmaceuticals
ndc-id:
ndc-product-code:70512-031
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-02-04
ended-marketing-on:
dosage-form:Ointment
strength:0.5 mg/1g
route:Topical
fda-application-number:ANDA210753
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Florone
labeller:Pharmacia and Upjohn Division of Pfizer
ndc-id:
ndc-product-code:0009-0199
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-02-06
ended-marketing-on:
dosage-form:Cream
strength:0.5 mg/1g
route:Topical
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Florone Crm 0.05%
labeller:Upjohn
ndc-id:
ndc-product-code:
dpd-id:00481807
ema-product-code:
ema-ma-number:
started-marketing-on:1980-12-31
ended-marketing-on:1998-08-12
dosage-form:Cream
strength:
route:Topical
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Florone Ont 0.05%
labeller:Upjohn
ndc-id:
ndc-product-code:
dpd-id:00481793
ema-product-code:
ema-ma-number:
started-marketing-on:1980-12-31
ended-marketing-on:1998-08-12
dosage-form:Ointment
strength:
route:Topical
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Psorcon
labeller:Dermik Laboratories, Inc.
ndc-id:
ndc-product-code:0066-0071
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-02-06
ended-marketing-on:
dosage-form:Ointment
strength:0.5 mg/1g
route:Topical
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Psorcon
labeller:Dermik Laboratories, Inc.
ndc-id:
ndc-product-code:0066-0069
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-01-16
ended-marketing-on:
dosage-form:Cream
strength:0.5 mg/60g
route:Topical
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Psorcon
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-2222
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1985-08-28
ended-marketing-on:2002-06-30
dosage-form:Ointment
strength:0.5 mg/1g
route:Topical
fda-application-number:NDA019260
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Psorcon
labeller:Taro Pharmaceuticals U.S.A., Inc.
ndc-id:
ndc-product-code:51672-5292
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-08-01
ended-marketing-on:
dosage-form:Cream
strength:5 mg/1g
route:Topical
fda-application-number:ANDA075508
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Psorcon E
labeller:Dermik Laboratories, Inc.
ndc-id:
ndc-product-code:0066-0275
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-02-06
ended-marketing-on:
dosage-form:Ointment
strength:0.5 mg/1g
route:Topical
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Psorcon E
labeller:Dermik Laboratories, Inc.
ndc-id:
ndc-product-code:0066-0272
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-08-04
ended-marketing-on:
dosage-form:Cream
strength:0.5 mg/1g
route:Topical
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC

混合物

name:Psorcon E
ingredients:Diflorasone
name:Florone
ingredients:Diflorasone
name:Psorcon
ingredients:Diflorasone
name:Psorcon E
ingredients:Diflorasone
name:Psorcon
ingredients:Diflorasone
name:Diflorasone Diacetate
ingredients:Diflorasone
name:Psorcon
ingredients:Diflorasone
name:ApexiCon E
ingredients:Diflorasone
name:Diflorasone Diacetate
ingredients:Diflorasone
name:Psorcon
ingredients:Diflorasone
name:Diflorasone Diacetate
ingredients:Diflorasone
name:Diflorasone Diacetate
ingredients:Diflorasone
name:ApexiCon E
ingredients:Diflorasone
name:Diflorasone Diacetate
ingredients:Diflorasone
name:Diflorasone Diacetate Oint
ingredients:Diflorasone
name:Diflorasone Diacetate
ingredients:Diflorasone
name:Diflorasone Diacetate
ingredients:Diflorasone
name:Diflorasone Diacetate
ingredients:Diflorasone
name:ApexiCon
ingredients:Diflorasone
name:Diflorasone Diacetate
ingredients:Diflorasone
name:Diflorasone Diacetate
ingredients:Diflorasone
name:Florone Ont 0.05%
ingredients:Diflorasone
name:Florone Crm 0.05%
ingredients:Diflorasone

包装者

name:Allergan Inc.
url:http://www.allergan.com
name:Dermik Labs
url:
name:Dispensing Solutions
url:http://www.drxdispensing.com
name:E. Fougera and Co.
url:http://www.fougera.com
name:Lake Erie Medical and Surgical Supply
url:
name:Nycomed Inc.
url:http://www.nycomed.com
name:Pharmacia Inc.
url:http://www.pharmaciaupjohn.com
name:Physicians Total Care Inc.
url:http://www.physicianstotalcare.com
name:Taro Pharmaceuticals USA
url:http://www.tarousa.com

生产者

generic:是; url:; name;Altana inc
generic:是; url:; name;Taro pharmaceuticals usa inc
generic:否; url:; name;Pharmacia and upjohn co
generic:否; url:; name;Sanofi aventis us llc
generic:是; url:; name;Taro pharmaceuticals inc

价格

Diflorasone 0.05% cream
1.5(单位：USD）
g
Psorcon 0.05% cream
3.45(单位：USD）
g
Diflorasone Diacetate 0.05% Ointment 15 gm Tube
38.05(单位：USD）
tube
Diflorasone Diacetate 0.05% Cream 15 gm Tube
38.25(单位：USD）
tube
Diflorasone Diacetate 0.05% Ointment 30 gm Tube
52.29(单位：USD）
tube
Diflorasone Diacetate 0.05% Cream 30 gm Tube
52.81(单位：USD）
tube
Diflorasone Diacetate 0.05% Ointment 60 gm Tube
100.5(单位：USD）
tube
Diflorasone Diacetate 0.05% Cream 60 gm Tube
101.11(单位：USD）
tube
Psorcon 0.05% Cream 60 gm Tube
137.58(单位：USD）
tube
Psorcon 0.05% Ointment 60 gm Tube
145.75(单位：USD）
tube

受影响的生物体

Humans and other mammals

剂量

form:Cream
route:Topical
strength:0.5 mg/1g
form:Cream
route:Topical
strength:
form:Ointment
route:Topical
strength:
form:Cream
route:Topical
strength:0.5 mg/60g
form:Cream
route:Topical
strength:5 mg/1g
form:Ointment
route:Topical
strength:0.5 mg/1g
form:Cream
route:Topical
strength:0.05 %
form:Ointment
route:Topical
strength:0.05 %

atc代码

Corticosteroids, potent (group III)
CORTICOSTEROIDS, PLAIN
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
DERMATOLOGICALS

fda标签

//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00223.pdf?1265922807

化学品安全技术说明书

//s3-us-west-2.amazonaws.com/drugbank/msds/DB00223.pdf?1265922745

专利

食物相互作用

药物相互作用

DB00072
Trastuzumab may increase the neutropenic activities of Diflorasone.
DB00864
Tacrolimus may increase the immunosuppressive activities of Diflorasone.
DB00388
The risk or severity of hypertension can be increased when Diflorasone is combined with Phenylephrine.
DB00357
The therapeutic efficacy of Diflorasone can be decreased when used in combination with Aminoglutethimide.
DB00030
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Insulin human.
DB00046
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Insulin lispro.
DB00047
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Insulin glargine.
DB00071
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Insulin pork.
DB00197
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Troglitazone.
DB00222
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Glimepiride.
DB00263
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Sulfisoxazole.
DB00280
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Disopyramide.
DB00284
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Acarbose.
DB00331
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Metformin.
DB00359
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Sulfadiazine.
DB00412
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Rosiglitazone.
DB00414
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Acetohexamide.
DB00468
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Quinine.
DB00491
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Miglitol.
DB00672
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Chlorpropamide.
DB00731
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Nateglinide.
DB00738
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Pentamidine.
DB00834
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Mifepristone.
DB00839
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Tolazamide.
DB00912
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Repaglinide.
DB00914
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Phenformin.
DB01015
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Sulfamethoxazole.
DB01016
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Glyburide.
DB01067
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Glipizide.
DB01120
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Gliclazide.
DB01124
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Tolbutamide.
DB01132
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Pioglitazone.
DB01200
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Bromocriptine.
DB01251
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Gliquidone.
DB01252
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Mitiglinide.
DB01261
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Sitagliptin.
DB01268
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Sunitinib.
DB01276
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Exenatide.
DB01277
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Mecasermin.
DB01278
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Pramlintide.
DB01289
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Glisoxepide.
DB01306
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Insulin aspart.
DB01307
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Insulin detemir.
DB01309
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Insulin glulisine.
DB01382
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Glymidine.
DB01700
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with AICA ribonucleotide.
DB04830
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Buformin.
DB04876
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Vildagliptin.
DB04878
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Voglibose.
DB05115
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with NN344.
DB05819
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with NBI-6024.
DB06011
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with AMG-222.
DB06127
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Bisegliptin.
DB06203
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Alogliptin.
DB06292
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Dapagliflozin.
DB06335
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Saxagliptin.
DB06655
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Liraglutide.
DB08382
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Gosogliptin.
DB08882
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Linagliptin.
DB08907
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Canagliflozin.
DB08962
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Glibornuride.
DB09022
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Benfluorex.
DB09038
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Empagliflozin.
DB09043
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Albiglutide.
DB09045
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Dulaglutide.
DB09198
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Lobeglitazone.
DB09199
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Netoglitazone.
DB09200
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Rivoglitazone.
DB09201
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Ciglitazone.
DB09265
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Lixisenatide.
DB09456
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Insulin beef.
DB09564
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Insulin degludec.
DB11567
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Insulin peglispro.
DB11568
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Insulin tregopil.
DB11698
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Ipragliflozin.
DB11723
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Dutogliptin.
DB11780
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Allicin.
DB11824
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Tofogliflozin.
DB11827
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Ertugliflozin.
DB11898
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with 2,4-thiazolidinedione.
DB11950
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Teneligliptin.
DB11992
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Omarigliptin.
DB12268
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Carmegliptin.
DB12412
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Gemigliptin.
DB12417
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Anagliptin.
DB12625
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Evogliptin.
DB12713
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Sotagliflozin.
DB12781
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Balaglitazone.
DB12935
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Remogliflozin etabonate.
DB13406
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Carbutamide.
DB13446
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Guar gum.
DB13675
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Metahexamide.
DB13928
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Semaglutide.
DB14027
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Taspoglutide.
DB14035
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Englitazone.
DB15171
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Tirzepatide.
DB15217
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Gastric inhibitory polypeptide.
DB00951
The serum concentration of Isoniazid can be decreased when it is combined with Diflorasone.
DB00091
The risk or severity of adverse effects can be increased when Diflorasone is combined with Cyclosporine.
DB00390
The risk or severity of adverse effects can be increased when Diflorasone is combined with Digoxin.
DB00511
The risk or severity of adverse effects can be increased when Diflorasone is combined with Acetyldigitoxin.
DB01078
The risk or severity of adverse effects can be increased when Diflorasone is combined with Deslanoside.
DB01396
The risk or severity of adverse effects can be increased when Diflorasone is combined with Digitoxin.
DB13401
The risk or severity of adverse effects can be increased when Diflorasone is combined with Metildigoxin.
DB13467
The risk or severity of adverse effects can be increased when Diflorasone is combined with Lanatoside C.
DB13537
The risk or severity of adverse effects can be increased when Diflorasone is combined with Gitoformate.
DB13691
The risk or severity of adverse effects can be increased when Diflorasone is combined with Acetyldigoxin.
DB00252
The serum concentration of Diflorasone can be decreased when it is combined with Phenytoin.
DB01320
The serum concentration of Diflorasone can be decreased when it is combined with Fosphenytoin.
DB14513
The serum concentration of Magnesium can be decreased when it is combined with Diflorasone.
DB01601
The serum concentration of Diflorasone can be increased when it is combined with Lopinavir.
DB00232
The risk or severity of electrolyte imbalance can be increased when Diflorasone is combined with Methyclothiazide.
DB00436
The risk or severity of electrolyte imbalance can be increased when Diflorasone is combined with Bendroflumethiazide.
DB00562
The risk or severity of electrolyte imbalance can be increased when Diflorasone is combined with Benzthiazide.
DB00606
The risk or severity of electrolyte imbalance can be increased when Diflorasone is combined with Cyclothiazide.
DB00774
The risk or severity of electrolyte imbalance can be increased when Diflorasone is combined with Hydroflumethiazide.
DB00880
The risk or severity of electrolyte imbalance can be increased when Diflorasone is combined with Chlorothiazide.
DB00999
The risk or severity of electrolyte imbalance can be increased when Diflorasone is combined with Hydrochlorothiazide.
DB01021
The risk or severity of electrolyte imbalance can be increased when Diflorasone is combined with Trichlormethiazide.
DB01324
The risk or severity of electrolyte imbalance can be increased when Diflorasone is combined with Polythiazide.
DB13430
The risk or severity of electrolyte imbalance can be increased when Diflorasone is combined with Mebutizide.
DB13532
The risk or severity of electrolyte imbalance can be increased when Diflorasone is combined with Cyclopenthiazide.
DB12530
The risk or severity of infection can be increased when Diflorasone is combined with Inebilizumab.

序列

实验性质

logP
2.1

外部标识符

resource：Drugs Product Database (DPD)
identifier：2049
resource：ChEBI
identifier：59750
resource：PubChem Compound
identifier：71415
resource：PubChem Substance
identifier：46504519
resource：KEGG Drug
identifier：D07827
resource：ChemSpider
identifier：64505
resource：PharmGKB
identifier：PA164749408
resource：Therapeutic Targets Database
identifier：DAP001184
resource：Wikipedia
identifier：Diflorasone
resource：ChEMBL
identifier：CHEMBL1201380
resource：ZINC
identifier：ZINC000005752191
resource：RxCUI
identifier：91311

外部链接

RxList
http://www.rxlist.com/cgi/generic/diflorasone.htm
Drugs.com
http://www.drugs.com/cdi/diflorasone-diacetate-cream.html

路径

目标

id:BE0000794
name:Glucocorticoid receptor
organism:Humans
action:agonist
Pearce DJ, Spencer L, Hu J, Balkrishnan R, Fleischer AB Jr, Feldman SR: Class I topical corticosteroid use by psoriasis patients in an academic practice. J Dermatolog Treat. 2004 Jul;15(4):235-8.
known-action:yes
name:Glucocorticoid receptor
general-function:Zinc ion binding
specific-function:Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth. Involved in chromatin remodeling. May play a negative role in adipogenesis through the regulation of lipolytic and antilipogenic genes expression.
gene-name:NR3C1
locus:5q31.3
cellular-location:Cytoplasm
transmembrane-regions:
signal-regions:
theoretical-pi:6.31
molecular-weight:85658.57
chromosome-location:5
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:7978GenAtlasNR3C1GenBank Gene DatabaseX03225GenBank Protein Database31680IUPHAR625Guide to Pharmacology625UniProtKBP04150UniProt AccessionGCR_HUMAN
synonyms:GRGRLNuclear receptor subfamily 3 group C member 1
amino-acid-sequence:>lcl|BSEQ0001584|Glucocorticoid receptor MDSKESLTPGREENPSSVLAQERGDVMDFYKTLRGGATVKVSASSPSLAVASQSDSKQRR LLVDFPKGSVSNAQQPDLSKAVSLSMGLYMGETETKVMGNDLGFPQQGQISLSSGETDLK LLEESIANLNRSTSVPENPKSSASTAVSAAPTEKEFPKTHSDVSSEQQHLKGQTGTNGGN VKLYTTDQSTFDILQDLEFSSGSPGKETNESPWRSDLLIDENCLLSPLAGEDDSFLLEGN SNEDCKPLILPDTKPKIKDNGDLVLSSPSNVTLPQVKTEKEDFIELCTPGVIKQEKLGTV YCQASFPGANIIGNKMSAISVHGVSTSGGQMYHYDMNTASLSQQQDQKPIFNVIPPIPVG SENWNRCQGSGDDNLTSLGTLNFPGRTVFSNGYSSPSMRPDVSSPPSSSSTATTGPPPKL CLVCSDEASGCHYGVLTCGSCKVFFKRAVEGQHNYLCAGRNDCIIDKIRRKNCPACRYRK CLQAGMNLEARKTKKKIKGIQQATTGVSQETSENPGNKTIVPATLPQLTPTLVSLLEVIE PEVLYAGYDSSVPDSTWRIMTTLNMLGGRQVIAAVKWAKAIPGFRNLHLDDQMTLLQYSW MFLMAFALGWRSYRQSSANLLCFAPDLIINEQRMTLPCMYDQCKHMLYVSSELHRLQVSY EEYLCMKTLLLLSSVPKDGLKSQELFDEIRMTYIKELGKAIVKREGNSSQNWQRFYQLTK LLDSMHEVVENLLNYCFQTFLDKTMSIEFPEMLAEIITNQIPKYSNGNIKKLLFHQK
gene-sequence:>lcl|BSEQ0020486|Glucocorticoid receptor (NR3C1) ATGGACTCCAAAGAATCATTAACTCCTGGTAGAGAAGAAAACCCCAGCAGTGTGCTTGCT CAGGAGAGGGGAGATGTGATGGACTTCTATAAAACCCTAAGAGGAGGAGCTACTGTGAAG GTTTCTGCGTCTTCACCCTCACTGGCTGTCGCTTCTCAATCAGACTCCAAGCAGCGAAGA CTTTTGGTTGATTTTCCAAAAGGCTCAGTAAGCAATGCGCAGCAGCCAGATCTGTCCAAA GCAGTTTCACTCTCAATGGGACTGTATATGGGAGAGACAGAAACAAAAGTGATGGGAAAT GACCTGGGATTCCCACAGCAGGGCCAAATCAGCCTTTCCTCGGGGGAAACAGACTTAAAG CTTTTGGAAGAAAGCATTGCAAACCTCAATAGGTCGACCAGTGTTCCAGAGAACCCCAAG AGTTCAGCATCCACTGCTGTGTCTGCTGCCCCCACAGAGAAGGAGTTTCCAAAAACTCAC TCTGATGTATCTTCAGAACAGCAACATTTGAAGGGCCAGACTGGCACCAACGGTGGCAAT GTGAAATTGTATACCACAGACCAAAGCACCTTTGACATTTTGCAGGATTTGGAGTTTTCT TCTGGGTCCCCAGGTAAAGAGACGAATGAGAGTCCTTGGAGATCAGACCTGTTGATAGAT GAAAACTGTTTGCTTTCTCCTCTGGCGGGAGAAGACGATTCATTCCTTTTGGAAGGAAAC TCGAATGAGGACTGCAAGCCTCTCATTTTACCGGACACTAAACCCAAAATTAAGGATAAT GGAGATCTGGTTTTGTCAAGCCCCAGTAATGTAACACTGCCCCAAGTGAAAACAGAAAAA GAAGATTTCATCGAACTCTGCACCCCTGGGGTAATTAAGCAAGAGAAACTGGGCACAGTT TACTGTCAGGCAAGCTTTCCTGGAGCAAATATAATTGGTAATAAAATGTCTGCCATTTCT GTTCATGGTGTGAGTACCTCTGGAGGACAGATGTACCACTATGACATGAATACAGCATCC CTTTCTCAACAGCAGGATCAGAAGCCTATTTTTAATGTCATTCCACCAATTCCCGTTGGT TCCGAAAATTGGAATAGGTGCCAAGGATCTGGAGATGACAACTTGACTTCTCTGGGGACT CTGAACTTCCCTGGTCGAACAGTTTTTTCTAATGGCTATTCAAGCCCCAGCATGAGACCA GATGTAAGCTCTCCTCCATCCAGCTCCTCAACAGCAACAACAGGACCACCTCCCAAACTC TGCCTGGTGTGCTCTGATGAAGCTTCAGGATGTCATTATGGAGTCTTAACTTGTGGAAGC TGTAAAGTTTTCTTCAAAAGAGCAGTGGAAGGACAGCACAATTACCTATGTGCTGGAAGG AATGATTGCATCATCGATAAAATTCGAAGAAAAAACTGCCCAGCATGCCGCTATCGAAAA TGTCTTCAGGCTGGAATGAACCTGGAAGCTCGAAAAACAAAGAAAAAAATAAAAGGAATT CAGCAGGCCACTACAGGAGTCTCACAAGAAACCTCTGAAAATCCTGGTAACAAAACAATA GTTCCTGCAACGTTACCACAACTCACCCCTACCCTGGTGTCACTGTTGGAGGTTATTGAA CCTGAAGTGTTATATGCAGGATATGATAGCTCTGTTCCAGACTCAACTTGGAGGATCATG ACTACGCTCAACATGTTAGGAGGGCGGCAAGTGATTGCAGCAGTGAAATGGGCAAAGGCA ATACCAGGTTTCAGGAACTTACACCTGGATGACCAAATGACCCTACTGCAGTACTCCTGG ATGTTTCTTATGGCATTTGCTCTGGGGTGGAGATCATATAGACAATCAAGTGCAAACCTG CTGTGTTTTGCTCCTGATCTGATTATTAATGAGCAGAGAATGACTCTACCCTGCATGTAC GACCAATGTAAACACATGCTGTATGTTTCCTCTGAGTTACACAGGCTTCAGGTATCTTAT GAAGAGTATCTCTGTATGAAAACCTTACTGCTTCTCTCTTCAGTTCCTAAGGACGGTCTG AAGAGCCAAGAGCTATTTGATGAAATTAGAATGACCTACATCAAAGAGCTAGGAAAAGCC ATTGTCAAGAGGGAAGGAAACTCCAGCCAGAACTGGCAGCGGTTTTATCAACTGACAAAA CTCTTGGATTCTATGCATGAAGTGGTTGAAAATCTCCTTAACTATTGCTTCCAAACATTT TTGGATAAGACCATGAGTATTGAATTCCCCGAGATGTTAGCTGAAATCATCACCAATCAG ATACCAAAATATTCAAATGGAAATATCAAAAAACTTCTGTTTCATCAAAAGTGA
pfams:PF00104Hormone_recepPF00105zf-C4PF02155GCR
go-classifiers:componentcytoplasmcomponentmitochondrial matrixcomponentnucleoplasmcomponentnucleusfunctionglucocorticoid receptor activityfunctionglucocorticoid-activated RNA polymerase II transcription factor binding transcription factor activityfunctionRNA polymerase II core promoter proximal region sequence-specific DNA bindingfunctionsteroid bindingfunctionsteroid hormone bindingfunctiontranscription factor activity, sequence-specific DNA bindingfunctiontranscriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific bindingfunctionzinc ion bindingprocesscellular response to steroid hormone stimulusprocesschromatin modificationprocessgene expressionprocesspositive regulation of transcription from RNA polymerase II promoterprocessregulation of transcription, DNA-templatedprocesssignal transductionprocesstranscription from RNA polymerase II promoterprocesstranscription initiation from RNA polymerase II promoterprocesstranscription, DNA-templated

酶

载体

运输工具

药物反应

效应

不良反应